Q-omics provides the consensus-scored SH2D4A profile across patient tissues and cancer cell-line models. SH2D4A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SH2D4A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SH2D4A RNA expression shows 18,529 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where SH2D4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH2D4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH2D4A survival associations across molecular data types. SH2D4A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH2D4A RNA expression–survival associations across cancer types. High SH2D4A expression shows unfavorable associations in LGG, PAAD and MESO, but favorable associations in HNSC, KIRC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SH2D4A RNA expression.
This table summarizes SH2D4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SH2D4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH2D4A shows lower tumor expression in KIRC and HNSC and higher tumor expression in THCA, BRCA, STAD and UCEC. The KIRC box plot shows higher SH2D4A RNA expression in normal versus tumor tissue (log2 FC = −1.140, t-test p < 0.001).
This table shows molecular features associated with SH2D4A in patient tissues and cancer cell lines. In patient samples, SH2D4A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH2D4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
